


PRODUCT INFORMATION



Mertansine

Item No. 22483

CAS Registry No.: 139504-50-0
Formal Name: N^{2'}-deacetyl-N^{2'}-(3-mercapto-1-oxopropyl)-maytansine
Synonym: DM 1 Compound
MF: C₃₅H₄₈ClN₃O₁₀S
FW: 738.3
Purity: ≥98%
UV/Vis.: λ_{max}: 233, 253 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Mertansine is supplied as a crystalline solid. A stock solution may be made by dissolving the mertansine in the solvent of choice, which should be purged with an inert gas. Mertansine is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of mertansine in these solvents is approximately 0.25, 20, and 33 mg/ml, respectively.

Mertansine is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, mertansine should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Mertansine has a solubility of approximately 0.03 mg/ml in a 1:30 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Mertansine is a thiol-containing derivative of maytansine that is cytotoxic to human epidermoid carcinoma KB and human breast cancer SK-BR-3 cells (IC₅₀ = 1.10 nM for both).¹ Formulations containing mertansine have been studied for the treatment of multiple myeloma and squamous cell carcinoma.^{2,3}

References

1. Widdison, W.C., Wilhelm, S.D., Cavanagh, E.E., *et al.* Semisynthetic maytansine analogues for the targeted treatment of cancer. *J. Med Chem.* **49(14)**, 4392-4408 (2006).
2. Berdeja, J.G. Lorvotuzumab mertansine: Antibody-drug-conjugate for CD56⁺ multiple myeloma. *Front. Biosci.* **19(1)**, 163-170 (2014).
3. Tijink, B.M., Buter, J., de Bree, R., *et al.* A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. *Clin. Cancer Res.* **12(20 Pt 1)**, 6064-6072 (2006).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/17/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM